Preparation and in vitro characterization of monoclonal antibody ranibizumab conjugated magnetic nanoparticles for ocular drug delivery

被引:9
作者
Ayata, Nese [1 ]
Sezer, Ali Demir [1 ]
Bucak, Seyda [2 ]
Turanli, Eda Tahir [3 ]
机构
[1] Marmara Univ, Fac Pharm, Dept Pharmaceut Biotechnol, Istanbul, Turkey
[2] Yeditepe Univ, Fac Engn, Dept Chem Engn, Istanbul, Turkey
[3] Istanbul Tech Univ, Fac Sci & Letters, Dept Mol Biol & Genet, Istanbul, Turkey
关键词
Ranibizumab; Monoclonal antibody; Drug delivery; Magnetic nanoparticles; Cell culture; ENDOTHELIAL GROWTH-FACTOR; MACULAR DEGENERATION; THERAPY; BEVACIZUMAB; PEGAPTANIB;
D O I
10.1590/s2175-97902020000118171
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Gold coated magnetite nanoparticles were prepared and coated with ranibizumab as an ocular drug delivery system. The surface morphologies of the nanoparticles were determined by Scanning Electron Microscopy (SEM). The size and surface charge were determined by using the dynamic light scattering (DLS) technique. Crystallographic properties of the gold coated Fe3O4 nanoparticles were recorded on X-ray diffractometer (X RD) the XRD pattern of nanoparticlees were shown to have uniqe Fe3O4 and gold peaks. Conjugation of ranibizumab onto nanoparticles was achieved using the physical adsorption method. The amount of ranibizumab on the surface of the nanoparticles was determined by thermogravimetric analysis (TGA). In the in vitro release studies performed using UV spectroscopy; it was found that almost 60% of antibodies were released within the first 30 minutes. Antibody activity after release studies was also proved with ELISA. Non-toxicity of gold coated Fe3O4 particles were proved with MTT. Results of the studies, showed that the antibody conjugated magnetic nanoparticle system could be a potential treatment system for ocular diseases.
引用
收藏
页码:1 / 15
页数:15
相关论文
共 45 条
  • [1] Ahmed O.S., 2014, LIFE SCI J, V11, P182
  • [2] Magnetic nanoparticles: preparation, physical properties, and applications in biomedicine
    Akbarzadeh, Abolfazl
    Samiei, Mohamad
    Davaran, Soodabeh
    [J]. NANOSCALE RESEARCH LETTERS, 2012, 7 : 1 - 13
  • [3] Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration
    Avery, RL
    Pieramici, DJ
    Rabena, MD
    Castellarin, AA
    Nasir, MA
    Giust, MJ
    [J]. OPHTHALMOLOGY, 2006, 113 (03) : 363 - 372
  • [4] Baca M, 1997, J BIOL CHEM, V272, P10678
  • [5] Bucak S, 2013, SYNTHESIS MAGNETITE
  • [6] Bucak S, 2012, RECENT ADVANCES IN NOVEL DRUG CARRIER SYSTEMS, P165, DOI 10.5772/52115
  • [7] Comparative effects of bevacizumab, ranibizumab and pegaptanib at intravitreal dose range on endothelial cells
    Carneiro, Angela
    Falcao, Manuel
    Pirraco, Ana
    Milheiro-Oliveira, Paula
    Falcao-Reis, Fernando
    Soares, Raquel
    [J]. EXPERIMENTAL EYE RESEARCH, 2009, 88 (03) : 522 - 527
  • [8] Selection and analysis of an optimized anti-VEGF antibody: Crystal structure of an affinity-matured Fab in complex with antigen
    Chen, Y
    Wiesmann, C
    Fuh, G
    Li, B
    Christinger, HW
    McKay, P
    de Vos, AM
    Lowman, HB
    [J]. JOURNAL OF MOLECULAR BIOLOGY, 1999, 293 (04) : 865 - 881
  • [9] Selective laser photo-thermal therapy of epithelial carcinoma using anti-EGFR antibody conjugated gold nanoparticles
    El-Sayed, Ivan H.
    Huang, Xiaohua
    El-Sayed, Mostafa A.
    [J]. CANCER LETTERS, 2006, 239 (01) : 129 - 135
  • [10] New pharmacologic approaches to therapy for age-related macular degeneration
    Eter, Nicole
    Krohne, Tim U.
    Holz, Frank G.
    [J]. BIODRUGS, 2006, 20 (03) : 167 - 179